EN DE
Watch Abbisko Cayman Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Abbisko Cayman Ltd (2256) fair value: what the stock is really worth

As of Oct 23, 2026: fair value (intrinsic value) of Abbisko Cayman Ltd stock HK$6.60, price HK$6.92, upside -4.6%, quality 72 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare · HK · Based in China · ISIN KYG0028A1085

AC Abbisko Cayman Ltd logo Thin data Oct 22, 2026

Abbisko Cayman Ltd

2256 · HK

NeutralQuality growthThe stock looks roughly fairly valued with average quality.

The stock costs about what our calculation considers fair.

Quality 72/100
Low debt
Generates free cash flow
Ranks above peers (7/11)
Fair value HK$6.60 · Fairly valued (−4.6%)
Mixed Growth (revenue YoY +18.3 %/yr in HKD)
Thin margins · 9.0% net margin (TTM)
Narrow moat 32/100 · thin data
Thin data
Watch Abbisko Cayman Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$19.62 HK$2.17 Fair Value HK$6.60 Oct 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 22, 2026.

How to read this chart

60‑month range HK$2.17 – HK$19.62 · fair‑value band HK$4.90 – HK$9.62 · the HK$6.92 price screens above the HK$6.60 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 22, 2026.

Follow Abbisko Cayman in your weekly email

Every Wednesday you see whether Abbisko Cayman is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union.

Show moreShow less

The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus host disease; and Irpagratinib (ABSK011), a small-molecule inhibitor of FGFR4, which is in pivotal stage and Phase Ib/II for the treatment of hepatocellular carcinoma.

It also engages in the development of ABSK061, which is in Phase Ib/II for the treatment of gastric cancer and achondroplasia; and ABSK043, which is in Phase Ib/II for the treatment of solid tumors and non-small cell lung cancer.

In addition, the company develops drugs in Phase I/Ia clinical trial, including ABSK121 for solid tumors; ABSK112 for non-small cell lung and breast cancers; ABK3376 for non-small cell lung cancer; ABSK131 for solid tumors; ABSK141 for solid tumors; and ABSK051 for solid tumors, as well as ABSK012, which is in preclinical stage for the treatment of rhabdomyosarcoma and solid tumors.

Further, it is involved in the development of drugs in IND enabling stage, such as ABSK211, ABSK191, and ABSK192 for solid tumors, as well as P151 for cardiometabolic; and drugs in lead optimization stage comprising P011, P018, P020, and P017 for solid tumors, as well as P023 for obesity and P022 for atopic dermatitis, asthma, and chronic obstructive pulmonary disease.

Additionally, the company provides advisory and management services. Abbisko Cayman Limited was founded in 2016 and is headquartered in Shanghai, China.

Stock analysis

Abbisko Cayman Ltd (2256) currently trades at HK$6.92, while our model-based Fair Value estimate is HK$6.60, so the stock looks roughly fairly valued today (gap 4.8%).

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$4.10 per share, and 1 of the 24 models we run sit above the HK$6.92 price.

Bear case: the Economic Profit group reads lowest at HK$1.41, and 23 of the 24 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$4.90 (bear) to HK$9.62 (bull), the price of HK$6.92 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Abbisko Cayman Ltd reported revenue of 596M CNY in FY2025 versus 22.7M CNY in FY2021, a compound +126.4%/yr. Reported net income was 53.8M CNY in FY2025.

Key figures

Market cap HK$5.0B (≈ $632M) Small · P/E ratio 112.3 · P/S ratio 10.1 · EPS (TTM) HK$0.5100 · Net margin 9.0% · Return on equity 2.9% · Return on assets (EBIT) −11.3% · Operating margin 4.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 54% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at −5%, 2256 screens richer than that median.

Fair Value models

Bear HK$4.90 Fair Value HK$6.60 Bull HK$9.62
Price HK$6.92 · Upside -4.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (HK$0.4178 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$2.71 HK$3.30 HK$5.05 78
Growth DCF HK$2.61 HK$3.47 HK$4.81 77
EPV HK$1.39 HK$1.41 HK$1.42 74
All 24 models by family
DCF Models
FCF DCF HK$2.71 HK$3.30 HK$5.05 78
Owner Earnings HK$2.36 HK$3.47 HK$5.39 73
5Y Revenue Exit HK$2.03 HK$2.41 HK$3.18 72
5Y EBITDA Exit HK$2.30 HK$2.96 HK$4.23 73
5Y P/E Exit HK$2.70 HK$4.36 HK$6.60 68
10Y Revenue Exit HK$2.27 HK$3.02 HK$3.36 66
10Y EBITDA Exit HK$2.45 HK$3.52 HK$5.25 66
10Y P/E Exit HK$2.70 HK$4.24 HK$6.72 61
Earnings-Based
Graham-Dodd HK$0.6000 HK$4.19 HK$5.87 61
Lynch FV HK$2.16 HK$3.09 HK$4.02 59
PEG = 1.0 HK$2.16 HK$3.09 HK$4.02 55
EPV HK$1.39 HK$1.41 HK$1.42 74
Multiples
P/E Multiple HK$1.46 HK$1.94 HK$2.43 63
P/S Multiple HK$1.13 HK$1.50 HK$1.88 58
P/B Multiple HK$10.63 HK$14.17 HK$17.71 55
EV/EBIT HK$1.30 HK$1.49 HK$1.68 66
EV/EBITDA HK$1.58 HK$1.87 HK$2.15 67
EV/Revenue HK$1.14 HK$1.31 HK$1.48 54
Asset-Based
NCAV (Graham) HK$1.84 HK$2.78 HK$3.48 54
Growth DCF
Growth DCF HK$2.61 HK$3.47 HK$4.81 77
Rev-Margin DCF HK$2.10 HK$2.58 HK$3.60 71
Economic Profit
Residual Income HK$2.04 HK$1.90 HK$1.85 68
ROIC Compounder HK$1.39 HK$1.41 HK$1.42 70
Growth Earnings
Growth-Adj P/E HK$2.87 HK$4.10 HK$5.33 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 72/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 30
How much profit the company makes from its sales and capital
Quality Growth 69
Are margins and returns getting better?
Cashflow 68
Do the profits arrive as real cash?
Financial strength 95
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 34
How calm the share price moves, does not count
Momentum 2
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 84
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 79/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+18.3%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+131.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,495.8% (2019) → 4.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+27.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+34.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about +24.8% a year for the price and +32.0% for the forecasts.
Forecast 2026 (sales)−54.5%
Forecast 2027 (sales)+94.6%
Projected 2028 (sales)+83.0%
Projected 2029 (sales)+71.4%
Projected 2030 (sales)+59.9%

Watch 2256, get fair value alerts →

Compare Abbisko Cayman Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 594 stocks

Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 72 · Top 25%
Fair Value upside −4.6% · Above median
Profitability
Return on equity (12 months) 2.9% · Above median
Return on assets 2.3% · Above median
Net margin (12 months) 9.0% · Above median
Operating margin (12 months) 4.6% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 112.3× · Priciest 25%
P/B 2.58× · Pricier than median
P/S (12 months) 8.10× · Pricier than median
Price / free cash flow 67.2× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)27 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)11 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $805.02 $1,275 +58% vs 2256
Vertex Pharmaceuticals Incorporated VRTX $535.17 $588.69 +10% vs 2256
Samsung Biologics Co 207940 1,466,000 KRW 1,612,600 KRW +10% vs 2256
WuXi Biologics (Cayman) Inc 2269 HK$45.80 HK$50.38 +10% vs 2256
argenx SE ARGX $890.05 $908.40 +2% vs 2256
Alnylam Pharmaceuticals, Inc ALNY $225.10 $217.88 −3% vs 2256
CSL Limited CSL A$196.70 A$178.56 −9% vs 2256
BeOne Medicines AG 6160 HK$231.40 HK$153.62 −34% vs 2256
Celltrion, Inc 068270 197,600 KRW 74,944 KRW −62% vs 2256
Royalty Pharma plc RPRX $62.15 $19.01 −69% vs 2256

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Abbisko Cayman Ltd · Fair Value
HK$6.60 −5%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Abbisko Cayman Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2256

Frequently asked questions

Is Abbisko Cayman Ltd (2256) overvalued or undervalued?
As of Oct 22, 2026, our model estimates a fair value of HK$6.60 versus a price of HK$6.92, about −5% upside (fairly valued).
What is the fair value of 2256?
Our model-based fair value for Abbisko Cayman Ltd is HK$6.60 (as of Oct 22, 2026), built from audited fundamentals. The current price: HK$6.92.
What is the quality score of 2256?
Abbisko Cayman Ltd has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Abbisko Cayman Ltd (2256)?
Our model-based price target is the fair value of HK$6.60 (as of Oct 22, 2026) from 24 valuation models. Cautious scenario HK$4.90, optimistic scenario HK$9.62. It is a calculation from audited fundamentals, not an analyst target.
What is the Abbisko Cayman Ltd stock forecast for 2026?
Our models put fair value at HK$6.60, about −5% upside versus a price of HK$6.92 (fairly valued). Cautious scenario HK$4.90, optimistic scenario HK$9.62. The calculation is refreshed regularly with new filings.
What is the revenue of Abbisko Cayman Ltd (2256)?
Abbisko Cayman Ltd reported trailing-twelve-month revenue of about HK$612M (latest available figure, as of Oct 22, 2026).
What growth is priced into Abbisko Cayman Ltd (2256)?
For today's price to be fair in a discounted-cash-flow model, Abbisko Cayman Ltd would have to grow free cash flow by +27.4 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 6 years revenue grew +131.9 % per year. As of Oct 22, 2026.
What discount rate (WACC) does the fair value of 2256 use?
Our models discount Abbisko Cayman Ltd at 12.4 %: a base by market capitalisation (small), damped by beta 1.21, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Abbisko Cayman Ltd that is +27.4 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Abbisko Cayman Ltd (2256) delivered so far?
Over the past 6 years revenue at Abbisko Cayman Ltd grew +131.9 % a year. The price currently implies +27.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Abbisko Cayman Ltd (2256) growing?
The median revenue growth in the sector is +5.7 % a year. That is the yardstick for the growth priced into Abbisko Cayman Ltd (+27.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Abbisko Cayman Ltd (2256)?
The free-cash-flow yield on the price is 1.67 %: that much free cash flow Abbisko Cayman Ltd produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Abbisko Cayman Ltd (2256)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Abbisko Cayman Ltd it is HK$6.60 per share (as of Oct 22, 2026), against a price of HK$6.92. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Abbisko Cayman Ltd stock overvalued or undervalued in 2026?
As of Oct 22, 2026, 2256 trades above its calculated fair value: price HK$6.92, fair value HK$6.60, a gap of about −5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2256?
No. The price is what the market pays today (HK$6.92); the fair value is what the company's own numbers justify (HK$6.60). For Abbisko Cayman Ltd the two are HK$0.3150 per share apart. That gap is exactly why we show both numbers side by side.
How much is Abbisko Cayman Ltd worth?
The market values Abbisko Cayman Ltd at about HK$5.0B (market capitalisation, as of Oct 22, 2026). Per share that is HK$6.92; our models calculate a fair value of HK$6.60 per share.
What do the bullish and bearish scenarios say about 2256?
Our models span a range for Abbisko Cayman Ltd: cautious scenario HK$4.90, base HK$6.60, optimistic HK$9.62 per share (as of Oct 22, 2026, price HK$6.92). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2256?
Abbisko Cayman Ltd trades at a price-to-earnings ratio of 112.3 (as of Oct 22, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$6.60 is built from several models across several years. Other multiples: P/B 2.6, P/S 8.1.
How solid is the balance sheet of Abbisko Cayman Ltd (2256)?
Balance-sheet figures for Abbisko Cayman Ltd (as of Oct 22, 2026): return on equity 2.9%. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
How far is 2256 from its 52-week high?
Abbisko Cayman Ltd trades at HK$6.92, about 54% below its 52-week high of HK$14.97 and at the low of HK$6.92 (as of Oct 23, 2026). Distance from the high says nothing about value: that is what the fair value of HK$6.60 is for.
Which stocks are comparable to Abbisko Cayman Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Abbisko Cayman Ltd stock attractive at the current price?
The data as of Oct 22, 2026: price HK$6.92, calculated fair value HK$6.60 (−5%), Quality Score 72/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2256 calculated?
We run Abbisko Cayman Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$6.60, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.5 % above its aggregate fair value. Abbisko Cayman Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Abbisko Cayman Ltd (2256)?
The closing price on Oct 23, 2026 was HK$6.92. Our model-based fair value is HK$6.60, about −5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Abbisko Cayman Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (HK$4.90 to HK$9.62) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Abbisko Cayman Ltd

How large is the market capitalisation of Abbisko Cayman Ltd (2256)?
The market capitalisation of Abbisko Cayman Ltd is HK$5.0B (≈ $632M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Abbisko Cayman Ltd (2256)?
The price-to-sales ratio of Abbisko Cayman Ltd is 10.1 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Abbisko Cayman Ltd (2256)?
Earnings per share at Abbisko Cayman Ltd are HK$0.5100 (price ÷ EPS = P/E 112.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Abbisko Cayman Ltd (2256)?
The net margin of Abbisko Cayman Ltd is 9.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Abbisko Cayman Ltd (2256)?
The return on equity (ROE) of Abbisko Cayman Ltd is 2.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Abbisko Cayman Ltd (2256)?
On an EBIT basis the return on assets of Abbisko Cayman Ltd is −11.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Abbisko Cayman Ltd (2256)?
The operating margin of Abbisko Cayman Ltd is 4.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast are earnings growing at Abbisko Cayman Ltd (2256)?
Earnings per share at Abbisko Cayman Ltd are growing +59.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Abbisko Cayman Ltd (2256) hold?
Abbisko Cayman Ltd holds more cash than debt, HK$446M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Abbisko Cayman Ltd in the live analysis

One click puts Abbisko Cayman Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.